April 15th 2025
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
April 15th 2025
April 14th 2025
March 10th 2025
March 7th 2025
March 6th 2025
March 5th 2025
March 31st 2025
March 3rd 2025
February 23rd 2025